US4186745A
(en)
|
1976-07-30 |
1980-02-05 |
Kauzlarich James J |
Porous catheters
|
US4500707A
(en)
|
1980-02-29 |
1985-02-19 |
University Patents, Inc. |
Nucleosides useful in the preparation of polynucleotides
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US5132418A
(en)
|
1980-02-29 |
1992-07-21 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US4973679A
(en)
|
1981-03-27 |
1990-11-27 |
University Patents, Inc. |
Process for oligonucleo tide synthesis using phosphormidite intermediates
|
US4668777A
(en)
|
1981-03-27 |
1987-05-26 |
University Patents, Inc. |
Phosphoramidite nucleoside compounds
|
US4373071A
(en)
|
1981-04-30 |
1983-02-08 |
City Of Hope Research Institute |
Solid-phase synthesis of polynucleotides
|
US6090406A
(en)
|
1984-04-12 |
2000-07-18 |
The Liposome Company, Inc. |
Potentiation of immune responses with liposomal adjuvants
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
US5153319A
(en)
|
1986-03-31 |
1992-10-06 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US4853228A
(en)
|
1987-07-28 |
1989-08-01 |
Micro-Pak, Inc. |
Method of manufacturing unilamellar lipid vesicles
|
US5047524A
(en)
|
1988-12-21 |
1991-09-10 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
US5262530A
(en)
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
DE69032284T2
(de)
|
1989-03-21 |
1998-10-08 |
Vical, Inc., San Diego, Calif. |
Expression von exogenen polynukleotidsequenzen in wirbeltieren
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
JPH0832638B2
(ja)
|
1989-05-25 |
1996-03-29 |
カイロン コーポレイション |
サブミクロン油滴乳剤を含んで成るアジュバント製剤
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
AU625013B2
(en)
|
1989-11-03 |
1992-06-25 |
Vanderbilt University |
Method of in vivo delivery of functioning foreign genes
|
US5674192A
(en)
|
1990-12-28 |
1997-10-07 |
Boston Scientific Corporation |
Drug delivery
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
JP3602530B2
(ja)
|
1991-03-07 |
2004-12-15 |
ヴァイロジェネティクス コーポレイション |
遺伝子操作したワクチン菌株
|
FR2676072B1
(fr)
*
|
1991-05-03 |
1994-11-18 |
Transgene Sa |
Vecteur de delivrance d'arn.
|
US5750390A
(en)
|
1992-08-26 |
1998-05-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
|
US5693535A
(en)
|
1992-05-14 |
1997-12-02 |
Ribozyme Pharmaceuticals, Inc. |
HIV targeted ribozymes
|
US5587308A
(en)
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
IL105914A0
(en)
|
1992-06-04 |
1993-10-20 |
Univ California |
Methods and compositions for in vivo gene therapy
|
JPH07509133A
(ja)
|
1992-07-17 |
1995-10-12 |
リボザイム・ファーマシューティカルズ・インコーポレイテッド |
動物疾患の処置のための方法および剤
|
US5474914A
(en)
|
1992-07-29 |
1995-12-12 |
Chiron Corporation |
Method of producing secreted CMV glycoprotein H
|
US20020102273A1
(en)
|
1995-08-08 |
2002-08-01 |
Robert B. Grieve |
Use of alphavirus expression vectors to produce parasite anitgens
|
EP1624068A1
(de)
|
1993-06-01 |
2006-02-08 |
Life Technologies Inc. |
Genetische Impfung mit kationischen Lipidstoffen
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
US5397307A
(en)
|
1993-12-07 |
1995-03-14 |
Schneider (Usa) Inc. |
Drug delivery PTCA catheter and method for drug delivery
|
JP3403233B2
(ja)
|
1994-01-20 |
2003-05-06 |
テルモ株式会社 |
バルーンカテーテル
|
IL112820A0
(en)
*
|
1994-03-07 |
1995-05-26 |
Merck & Co Inc |
Coordinate in vivo gene expression
|
JPH08511956A
(ja)
|
1994-04-07 |
1996-12-17 |
アクゾ・ノベル・エヌ・ベー |
Rnaを含む凍結乾燥組成物
|
US5993850A
(en)
|
1994-09-13 |
1999-11-30 |
Skyepharma Inc. |
Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
DE69536153D1
(de)
|
1994-11-17 |
2011-05-05 |
Ich Productions Ltd |
Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors
|
WO1996017072A2
(en)
|
1994-11-30 |
1996-06-06 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
JPH11504802A
(ja)
*
|
1994-11-30 |
1999-05-11 |
カイロン コーポレイション |
組換えアルファウイルスベクター
|
US6071890A
(en)
|
1994-12-09 |
2000-06-06 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
|
US5965434A
(en)
|
1994-12-29 |
1999-10-12 |
Wolff; Jon A. |
Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
|
US5664701A
(en)
|
1995-01-25 |
1997-09-09 |
Uniplast, Inc. |
Glue gun system with removable cartridges
|
US5700642A
(en)
|
1995-05-22 |
1997-12-23 |
Sri International |
Oligonucleotide sizing using immobilized cleavable primers
|
US5792462A
(en)
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
AU727923B2
(en)
|
1995-09-27 |
2001-01-04 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Production of infectious respiratory syncytial virus from cloned nucleotide sequences
|
DK0871757T3
(da)
*
|
1995-11-28 |
2003-07-14 |
Univ Johns Hopkins Med |
Konditionelt replikerende virale vektorer og deres anvendelse
|
EP0880360B1
(de)
|
1996-02-12 |
2002-10-09 |
Cobra Therapeutics Limited |
Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
|
DE19605548A1
(de)
|
1996-02-15 |
1997-09-04 |
Boehringer Ingelheim Int |
Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
|
DE19612967A1
(de)
|
1996-04-01 |
1997-10-02 |
Behringwerke Ag |
Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
|
US6451592B1
(en)
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
WO1998000110A1
(en)
|
1996-07-03 |
1998-01-08 |
University Of Pittsburgh |
Emulsion formulations for hydrophilic active agents
|
EP0938298B1
(de)
|
1996-09-13 |
2002-12-04 |
Lipoxen Technologies Limited |
Liposomenzusammensetzung
|
US7384923B2
(en)
|
1999-05-14 |
2008-06-10 |
Lipoxen Technologies Limited |
Liposomes
|
US6395302B1
(en)
|
1996-11-19 |
2002-05-28 |
Octoplus B.V. |
Method for the preparation of microspheres which contain colloidal systems
|
EP1027033B1
(de)
|
1997-05-14 |
2009-07-22 |
The University Of British Columbia |
Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
|
US6048546A
(en)
|
1997-07-31 |
2000-04-11 |
Sandia Corporation |
Immobilized lipid-bilayer materials
|
US6060308A
(en)
|
1997-09-04 |
2000-05-09 |
Connaught Laboratories Limited |
RNA respiratory syncytial virus vaccines
|
US6090619A
(en)
|
1997-09-08 |
2000-07-18 |
University Of Florida |
Materials and methods for intracellular delivery of biologically active molecules
|
US6129705A
(en)
|
1997-10-01 |
2000-10-10 |
Medtronic Ave, Inc. |
Drug delivery and gene therapy delivery system
|
JP2002500003A
(ja)
|
1997-11-28 |
2002-01-08 |
ザ・クラウン・イン・ザ・ライト・オヴ・ザ・クイーンズランド・デパートメント・オヴ・ヘルス |
フラビウイルスの発現および送達のシステム
|
US6009406A
(en)
|
1997-12-05 |
1999-12-28 |
Square D Company |
Methodology and computer-based tools for re-engineering a custom-engineered product line
|
GB9726555D0
(en)
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Vaccine
|
WO1999055310A1
(en)
|
1998-04-27 |
1999-11-04 |
Altus Biologics Inc. |
Stabilized protein crystals, formulations containing them and methods of making them
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
US6517842B1
(en)
|
1998-06-29 |
2003-02-11 |
The United States Of America As Represented By The Secretary Of The Army |
Marburg virus vaccines
|
EP1096921B1
(de)
|
1998-07-20 |
2003-04-16 |
Protiva Biotherapeutics Inc. |
In liposomen verkapselte nukleinsäurekomplexe
|
EP1141313A2
(de)
*
|
1998-12-31 |
2001-10-10 |
Chiron Corporation |
Verbesserte exprimierung von hiv polypeptiden und herstellung von virusähnliche partikeln
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
DE69923840T2
(de)
|
1999-09-09 |
2006-04-06 |
Curevac Gmbh |
Transfer von mRNAs unter Verwendung von polykationischen Verbindungen
|
CA2388045C
(en)
|
1999-10-20 |
2014-02-11 |
Tzyy-Choou Wu |
Nucleic acid immunogenic compositions encoding hsp-antigen chimera
|
US8541008B2
(en)
|
1999-11-19 |
2013-09-24 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Pharmaceutical compositions and methods to vaccinate against candidiasis
|
EP1103610A1
(de)
|
1999-11-26 |
2001-05-30 |
Introgene B.V. |
Impfstoffherstellung von immortalisierten Säugetierzellinien
|
US20030212022A1
(en)
|
2001-03-23 |
2003-11-13 |
Jean-Marie Vogel |
Compositions and methods for gene therapy
|
WO2001079253A1
(en)
|
2000-04-18 |
2001-10-25 |
Human Genome Sciences, Inc. |
Extracellular matrix polynucleotides, polypeptides, and antibodies
|
JP2003535832A
(ja)
|
2000-06-09 |
2003-12-02 |
ブリカス,テニ |
ポリヌクレオチドおよび薬物の標的化リポソームへのカプセル化
|
AU2001276619A1
(en)
|
2000-07-03 |
2002-01-14 |
Chiron S.P.A. |
Immunisation against chlamydia pneumoniae
|
WO2002009645A2
(en)
|
2000-08-01 |
2002-02-07 |
The Johns Hopkins University |
Intercellular transport protein linked to an antigen as a molecular vaccine
|
US20040142474A1
(en)
|
2000-09-14 |
2004-07-22 |
Expression Genetics, Inc. |
Novel cationic lipopolymer as a biocompatible gene delivery agent
|
SG137691A1
(en)
|
2000-09-28 |
2007-12-28 |
Chiron Corp |
Microparticles for delivery of the heterologous nucleic acids
|
EP2189473A3
(de)
|
2000-10-27 |
2010-08-11 |
Novartis Vaccines and Diagnostics S.r.l. |
Nukleinsäure und Proteine von Gruppen A und B Streptokokken
|
US7445924B2
(en)
|
2000-11-23 |
2008-11-04 |
Bavarian Nordic A/S |
Modified Vaccinia Ankara virus variant and cultivation method
|
WO2002079239A2
(en)
|
2001-01-31 |
2002-10-10 |
U.S. Army Medical Research Institute Of Infectious Diseases |
Chimeric filovirus glycoprotein
|
EP1363660A4
(de)
|
2001-02-01 |
2006-06-21 |
Univ Johns Hopkins |
"überlegene molekulare vakzine auf basis selbstreplizierender rna, suizid-dna oder nacktem dna-vektor, zur verknüpfung von antigen mit polypeptid zur förderung der antigenpräsentation"
|
US20030040498A1
(en)
|
2001-03-14 |
2003-02-27 |
Ansardi David Calvert |
Oncolytic RNA replicons
|
AU2002306736A1
(en)
|
2001-03-16 |
2002-10-03 |
Johns Hopkins University |
A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
|
US20030203865A1
(en)
|
2001-04-30 |
2003-10-30 |
Pierrot Harvie |
Lipid-comprising drug delivery complexes and methods for their production
|
US20030077251A1
(en)
|
2001-05-23 |
2003-04-24 |
Nicolas Escriou |
Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins
|
DE50214200D1
(de)
|
2001-06-05 |
2010-03-25 |
Curevac Gmbh |
Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
|
EP1423142A1
(de)
|
2001-08-31 |
2004-06-02 |
Chiron SRL. |
Helicobacter pylori impfung mit einer kombination der proteine caga, vaca und nap
|
DE60233061D1
(de)
|
2001-09-06 |
2009-09-03 |
Alphavax Inc |
Alphavirus replikon-vektorsysteme
|
US20050163832A1
(en)
|
2002-02-13 |
2005-07-28 |
Vladimir Torchilin |
Intracellular delivery of therapeutic agents
|
DE10207177A1
(de)
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Fakultativ kationische Lipide
|
US6861410B1
(en)
|
2002-03-21 |
2005-03-01 |
Chiron Corporation |
Immunological adjuvant compositions
|
MXPA04011249A
(es)
|
2002-05-14 |
2005-06-06 |
Chiron Srl |
Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
|
US7901708B2
(en)
|
2002-06-28 |
2011-03-08 |
Protiva Biotherapeutics, Inc. |
Liposomal apparatus and manufacturing methods
|
ATE348633T1
(de)
|
2002-07-05 |
2007-01-15 |
Lipoxen Technologies Ltd |
Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
|
US20060251620A1
(en)
|
2002-08-22 |
2006-11-09 |
Lidia Ivanova |
Inducible alphaviral/orip based gene expression system
|
WO2004024919A1
(en)
|
2002-09-13 |
2004-03-25 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
DK1585812T3
(en)
*
|
2002-12-13 |
2017-04-10 |
Alphavax Inc |
MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES
|
EP1587816B1
(de)
|
2002-12-23 |
2010-06-16 |
Vical Incorporated |
Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
|
US8338583B2
(en)
|
2003-02-04 |
2012-12-25 |
Bar-Ilan University |
Snornai-small nucleolar RNA degradation by RNA interference in trypanosomatids
|
US20040228842A1
(en)
*
|
2003-02-27 |
2004-11-18 |
Shan Lu |
Compositions and methods for cytomegalovirus treatment
|
CA2518546C
(en)
|
2003-03-20 |
2012-11-13 |
Alphavax, Inc. |
Improved alphavirus replicons and helper constructs
|
CA2520386A1
(en)
|
2003-03-27 |
2004-10-14 |
Children's Hospital, Inc. |
Nontypeable haemophilus influenzae virulence factors
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
EP1637144A4
(de)
|
2003-05-30 |
2010-01-13 |
Nippon Shinyaku Co Ltd |
Oligonucleinsäure enthaltender komposit und diesen enthaltende pharmazeutische zusammensetzung
|
US20100255002A1
(en)
|
2003-06-26 |
2010-10-07 |
Chiron Corporation |
Immunogenic compositions for chlamydia trachomatis
|
EP1651666B1
(de)
*
|
2003-07-11 |
2009-05-27 |
Alphavax, Inc. |
Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
|
US7368537B2
(en)
|
2003-07-15 |
2008-05-06 |
Id Biomedical Corporation Of Quebec |
Subunit vaccine against respiratory syncytial virus infection
|
EP1648519B1
(de)
|
2003-07-16 |
2014-10-08 |
Protiva Biotherapeutics Inc. |
Lipid verkapselte interferierende rns
|
ES2505695T3
(es)
|
2003-07-31 |
2014-10-10 |
Novartis Vaccines And Diagnostics, Inc. |
Composiciones inmunógenas para Streptococcus pyogenes
|
EP1512393A1
(de)
|
2003-09-08 |
2005-03-09 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG |
Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen
|
EP1528101A1
(de)
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalisierte Vogel-Zelllinien für die Produktion von Viren
|
US20050208020A1
(en)
|
2003-11-12 |
2005-09-22 |
Doolan Denise L |
Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
|
US7303881B2
(en)
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
ATE420965T1
(de)
*
|
2004-05-18 |
2009-01-15 |
Alphavax Inc |
Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
|
US20060024670A1
(en)
|
2004-05-18 |
2006-02-02 |
Luke Catherine J |
Influenza virus vaccine composition and methods of use
|
GB0411428D0
(en)
|
2004-05-21 |
2004-06-23 |
Got A Gene Ab |
Vectors
|
EP1766034B1
(de)
|
2004-05-21 |
2014-03-19 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus-vektoren für impfstoffe gegen das influenza virus
|
AU2005252273B2
(en)
|
2004-06-07 |
2011-04-28 |
Arbutus Biopharma Corporation |
Lipid encapsulated interfering RNA
|
AU2005251403B2
(en)
|
2004-06-07 |
2011-09-01 |
Arbutus Biopharma Corporation |
Cationic lipids and methods of use
|
EP1773403B1
(de)
|
2004-07-09 |
2018-04-25 |
The University of North Carolina At Chapel Hill |
Auf alphavirus basierende adjuvanzien
|
WO2006007712A1
(en)
|
2004-07-19 |
2006-01-26 |
Protiva Biotherapeutics, Inc. |
Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
|
JP5086082B2
(ja)
|
2004-10-01 |
2012-11-28 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
C型肝炎ウイルス複製系
|
AU2005306075A1
(en)
|
2004-11-19 |
2006-05-26 |
Novosom Ag |
Improvements in or relating to pharmaceutical compositions for local administration
|
GB2421025A
(en)
|
2004-12-09 |
2006-06-14 |
Oxxon Therapeutics Ltd |
HSV vaccination vectors
|
CA2597724A1
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
AU2006214064B2
(en)
|
2005-02-18 |
2012-04-26 |
J. Craig Venter Institute, Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
MX291624B
(es)
|
2005-02-18 |
2011-11-04 |
Novartis Vaccines & Diagnostic |
Inmunogenos de escherichia coli uropatogenica.
|
US20080138431A1
(en)
|
2005-03-02 |
2008-06-12 |
James Edward Eyles |
Pharmaceutical Composition
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AU2006235045A1
(en)
|
2005-03-30 |
2006-10-19 |
J. Craig Venter Institute, Inc. |
Haemophilus influenzae type b
|
BRPI0609362A2
(pt)
*
|
2005-04-11 |
2010-03-30 |
Us Gov Health & Human Serv |
vetor de adenovìrus recombinante, adenovìrus recombinante, composição imunogênica e método para a produção da referida composição imunogênica
|
US7618393B2
(en)
|
2005-05-03 |
2009-11-17 |
Pharmajet, Inc. |
Needle-less injector and method of fluid delivery
|
JP2008544745A
(ja)
|
2005-05-12 |
2008-12-11 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
Chlamydiatrachomatisのための免疫原性組成物
|
US8703095B2
(en)
|
2005-07-07 |
2014-04-22 |
Sanofi Pasteur S.A. |
Immuno-adjuvant emulsion
|
EP1909758A1
(de)
|
2005-08-02 |
2008-04-16 |
I.D.M. Immuno-Designed Molecules |
Verfahren zur herstelung von liposomalen formulierungen
|
US7951384B2
(en)
|
2005-08-05 |
2011-05-31 |
University Of Massachusetts |
Virus-like particles as vaccines for paramyxovirus
|
ES2735531T3
(es)
|
2005-08-23 |
2019-12-19 |
Univ Pennsylvania |
ARN que contiene nucleósidos modificados y métodos de uso del mismo
|
WO2007107304A2
(en)
|
2006-03-17 |
2007-09-27 |
Novosom Ag |
An efficient method for loading amphoteric liposomes with nucleic acid active substances
|
EP1764089A1
(de)
|
2005-09-15 |
2007-03-21 |
Novosom AG |
Serumstabile liposomale Formulierungen enthaltend amphotere II Lipidmischungen
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
AU2006297220B8
(en)
|
2005-09-29 |
2013-01-31 |
Elan Pharmaceuticals, Inc. |
Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
JP2007112768A
(ja)
|
2005-10-24 |
2007-05-10 |
Kyoto Univ |
肝指向性リポソーム組成物
|
EP1954306A2
(de)
|
2005-10-25 |
2008-08-13 |
Novartis Vaccines and Diagnostics S.r.l. |
Zusammensetzungen mit yersinia pestis-antigenen
|
CA2630220C
(en)
|
2005-11-22 |
2020-10-13 |
Doris Coit |
Norovirus and sapovirus antigens
|
EP1954252B1
(de)
|
2005-12-02 |
2016-02-03 |
GlaxoSmithKline Biologicals SA |
Nanopartikel für den einsatz in immunogenen zusammensetzungen
|
EP3031469B1
(de)
*
|
2006-06-07 |
2023-08-23 |
The Trustees Of Princeton University |
Cytomegalovirus-oberflächenproteinkomplex zur verwendung in impfstoffen und als ein wirkstoff-target
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
CN101506381B
(zh)
|
2006-06-21 |
2012-09-05 |
斯克里普斯研究学院 |
针对肿瘤基质抗原fap的dna组合物及其使用方法
|
DK2049559T3
(da)
*
|
2006-07-28 |
2013-03-25 |
Univ Pennsylvania |
Forbedrede HPV vacciner
|
JP2010500399A
(ja)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
尿路病原性大腸菌由来の免疫原
|
WO2008033966A2
(en)
|
2006-09-12 |
2008-03-20 |
Alphavax, Inc. |
Alphavirus replicon particles matched to protein antigens as immunological adjuvants
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
JP2010519203A
(ja)
|
2007-02-16 |
2010-06-03 |
メルク・シャープ・エンド・ドーム・コーポレイション |
生物活性分子の活性を強化するための組成物及び方法
|
US20100196492A1
(en)
|
2007-03-08 |
2010-08-05 |
Green Jordan J |
Electrostatic coating of particles for drug delivery
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
EP2147102B1
(de)
|
2007-03-29 |
2014-01-15 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
|
US8748591B2
(en)
|
2007-04-17 |
2014-06-10 |
The Board Of Regents Of The University Of Texas System |
Chimeric sindbis-western equine encephalitis virus and uses thereof
|
DK2494993T3
(en)
|
2007-05-04 |
2018-11-12 |
Marina Biotech Inc |
Amino acid lipids and uses thereof
|
EP2152890A1
(de)
*
|
2007-05-23 |
2010-02-17 |
MannKind Corporation |
Multicistronische vektoren und verfahren zu deren konstruktion
|
DE102007029471A1
(de)
|
2007-06-20 |
2008-12-24 |
Novosom Ag |
Neue fakultativ kationische Sterole
|
CN101802199B
(zh)
*
|
2007-06-21 |
2012-08-22 |
阿尔法瓦克斯公司 |
用于α病毒结构蛋白表达的无启动子盒
|
EP2173771A1
(de)
|
2007-07-04 |
2010-04-14 |
Ribovax Biotechnologies SA |
Antikörper gegen das humane cytomegalie-virus (hcmv)
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
US20110177155A1
(en)
|
2007-08-21 |
2011-07-21 |
Immune Disease Institute, Inc. |
Methods of delivery of agents to leukocytes and endothelial cells
|
GB0717187D0
(en)
|
2007-09-04 |
2007-10-17 |
Novartis Ag |
Compositions comprising yersinia pestis antigens
|
WO2009042794A2
(en)
|
2007-09-26 |
2009-04-02 |
Vanderbilt University |
Venezuelan equine encephalitis replicons expressing paramyxovirus glycoproteins as vaccine
|
EP2042193A1
(de)
|
2007-09-28 |
2009-04-01 |
Biomay AG |
RNA-Impfstoffe
|
US9234181B2
(en)
|
2007-11-26 |
2016-01-12 |
Novartis Ag |
RNA expression cassette and cells for making alphavirus particles
|
EP2067749A1
(de)
|
2007-11-29 |
2009-06-10 |
Total Petrochemicals France |
Verfahren zur Reinigung einer wässrigen Phase mit Polyaromatika
|
WO2009074861A2
(en)
|
2007-12-10 |
2009-06-18 |
Powderject Research Limited |
Improved vaccine
|
WO2009111088A2
(en)
|
2008-01-02 |
2009-09-11 |
The Johns Hopkins University |
Antitumor immunization by liposomal delivery of vaccine to the spleen
|
CA3044134A1
(en)
|
2008-01-02 |
2009-07-09 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
ITMI20081249A1
(it)
|
2008-07-09 |
2010-01-09 |
Novartis Vaccines & Diagnostic |
Immunogeni di escherichia coli con solubilità migliorata.
|
WO2009109860A2
(en)
|
2008-03-06 |
2009-09-11 |
Novartis Ag |
Mutant forms of chlamydia htra
|
CN102119217B
(zh)
|
2008-04-15 |
2015-06-03 |
普洛体维生物治疗公司 |
用于核酸递送的新型制剂
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
WO2009132131A1
(en)
|
2008-04-22 |
2009-10-29 |
Alnylam Pharmaceuticals, Inc. |
Amino lipid based improved lipid formulation
|
WO2009132206A1
(en)
|
2008-04-25 |
2009-10-29 |
Liquidia Technologies, Inc. |
Compositions and methods for intracellular delivery and release of cargo
|
US20100040650A1
(en)
|
2008-05-30 |
2010-02-18 |
Crowe Jr James E |
Virus-Like paramyxovirus particles and vaccines
|
EP2130912A1
(de)
|
2008-06-04 |
2009-12-09 |
Institut für Viruskrankeiten und Immunprophylaxe |
Ein RNA-basiertes virales Vektorsystem bereitstellende Pestivirusreplikone
|
US20110229969A1
(en)
*
|
2008-06-25 |
2011-09-22 |
Volker Sandig |
Cell Line for Propagation of Highly Attenuated AlphaViruses
|
EP2310045A1
(de)
|
2008-06-25 |
2011-04-20 |
Novartis AG |
Schnelle antworten auf verzögerte booster-immunisierungen
|
BRPI0916443A2
(pt)
|
2008-07-16 |
2017-10-31 |
Inst Res Biomedicine |
anticorpos de neutralização de citomegalovírus humanos e uso dos mesmos
|
CN102143974B
(zh)
*
|
2008-07-16 |
2015-03-25 |
生命医学研究学会 |
人巨细胞病毒中和抗体及其用途
|
JP2010025644A
(ja)
|
2008-07-16 |
2010-02-04 |
Kochi Univ Of Technology |
硝酸イオンの呈色試薬並びにこれを用いた硝酸イオンの検出及び定量方法
|
US20110280949A1
(en)
|
2008-08-06 |
2011-11-17 |
Padma Malyala |
Microparticles for use in immunogenic compositions
|
CL2008002322A1
(es)
|
2008-08-07 |
2009-06-05 |
Univ Concepcion |
Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna.
|
KR101661746B1
(ko)
|
2008-08-13 |
2016-09-30 |
캘리포니아 인스티튜트 오브 테크놀로지 |
캐리어 나노입자, 그리고 관련된 조성물, 방법 및 시스템
|
WO2010019437A1
(en)
|
2008-08-15 |
2010-02-18 |
Novartis Ag |
Alphavirus packaging cell lines
|
WO2010036948A2
(en)
|
2008-09-26 |
2010-04-01 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Dna prime/inactivated vaccine boost immunization to influenza virus
|
CA2740000C
(en)
|
2008-10-09 |
2017-12-12 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
JP6087504B2
(ja)
|
2008-11-07 |
2017-03-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
アミノアルコールリピドイドおよびその使用
|
KR102344392B1
(ko)
|
2008-11-10 |
2021-12-28 |
알닐람 파마슈티칼스 인코포레이티드 |
치료제 운반용 신규 지질 및 조성물
|
JP6046348B2
(ja)
|
2008-11-18 |
2016-12-14 |
タケダ ヴァクシーンズ, インコーポレイテッド |
Rsvfvlpならびにその製造および使用の方法
|
AU2010208035B2
(en)
|
2009-01-29 |
2016-06-23 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
JP5830009B2
(ja)
|
2009-04-14 |
2015-12-09 |
ノバルティス アーゲー |
Staphylococcusaureusに対して免疫化するための組成物
|
JP5889783B2
(ja)
|
2009-05-05 |
2016-03-22 |
テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation |
免疫細胞へオリゴヌクレオチドを送達する方法
|
EA201791744A3
(ru)
|
2009-06-10 |
2018-07-31 |
Арбутус Биофарма Корпорэйшн |
Улучшенная липидная композиция
|
CA2767127A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
EP2450031B1
(de)
|
2009-07-02 |
2018-08-29 |
Konica Minolta Holdings, Inc. |
Verfahren zur herstellung von liposomen durch ein zweistufen-emulgierverfahren unter verwendung der äusseren wässrigen phase mit spezifischen dispergiermitteln, verfahren zur herstellung der liposom-dispersion oder trockenpulver durch verwendung des verfahrens zur herstellung von liposomen und liposomdispersion oder trockenpulver daraus
|
CA2766907A1
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
US20120164176A1
(en)
|
2009-07-15 |
2012-06-28 |
Kurt Swanson |
Rsv f protein compositions amd methods for making same
|
DK2453914T3
(en)
|
2009-07-16 |
2018-10-08 |
Vaxil Biotherapeutics Ltd |
ANTIGEN-SPECIFIC MULTIPLE PIT-BASED ANTI-INFECTIOUS VACCINES
|
DK2459231T3
(en)
|
2009-07-31 |
2016-09-05 |
Ethris Gmbh |
RNA with a combination of unmodified and modified nucleotides for protein expression
|
TWI445708B
(zh)
|
2009-09-02 |
2014-07-21 |
Irm Llc |
作為tlr活性調節劑之化合物及組合物
|
AU2010290896B2
(en)
|
2009-09-02 |
2014-07-03 |
Glaxosmithkline Biologicals S.A. |
Immunogenic compositions including TLR activity modulators
|
US20110070260A1
(en)
|
2009-09-09 |
2011-03-24 |
Baric Ralph S |
Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
|
CN107028886A
(zh)
|
2009-11-04 |
2017-08-11 |
不列颠哥伦比亚大学 |
含有核酸的脂质粒子及相关的方法
|
US20110112353A1
(en)
|
2009-11-09 |
2011-05-12 |
Circulite, Inc. |
Bifurcated outflow cannulae
|
NZ700688A
(en)
|
2009-12-01 |
2016-02-26 |
Shire Human Genetic Therapies |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
US9687550B2
(en)
|
2009-12-07 |
2017-06-27 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
EP3623474A1
(de)
|
2009-12-07 |
2020-03-18 |
The Trustees of The University of Pennsylvania |
Rna-präparate mit gereinigter modifizierter rna zur neuprogrammierung von zellen
|
ES2749426T3
(es)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Métodos y composiciones para administración de ácidos nucleicos
|
AU2010334911A1
(en)
|
2009-12-23 |
2012-07-12 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
ES2536429T3
(es)
|
2010-01-24 |
2015-05-25 |
Novartis Ag |
Micropartículas de polímero biodegradables irradiadas
|
WO2011112717A1
(en)
|
2010-03-09 |
2011-09-15 |
Biomedical Research Models, Inc. |
A novel mucosal vaccination approach for herpes simplex virus type-2
|
JP2013529894A
(ja)
|
2010-04-07 |
2013-07-25 |
ノバルティス アーゲー |
パルボウイルスb19のウイルス様粒子を生成するための方法
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
WO2012006369A2
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Immunisation of large mammals with low doses of rna
|
JP6025721B2
(ja)
|
2010-07-06 |
2016-11-16 |
ノバルティス アーゲー |
カチオン性水中油型エマルジョン
|
RS63817B1
(sr)
|
2010-07-06 |
2023-01-31 |
Glaxosmithkline Biologicals Sa |
Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
DK3243526T3
(da)
|
2010-07-06 |
2020-02-17 |
Glaxosmithkline Biologicals Sa |
Levering af rna til at udløse flere immunsignalveje
|
EP2590626B1
(de)
*
|
2010-07-06 |
2015-10-28 |
GlaxoSmithKline Biologicals SA |
Liposomen aus lipiden, die einen vorteilhaften pka-wert zur verabreichung von rna besitzen
|
CA2804501C
(en)
|
2010-07-06 |
2021-01-26 |
Novartis Ag |
Noro virus derived immunogenic compositions and methods
|
US8898852B2
(en)
|
2010-08-04 |
2014-12-02 |
Honeywell International Inc. |
Air burst to clear detection window
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP4119155A1
(de)
|
2010-08-31 |
2023-01-18 |
GlaxoSmithKline Biologicals S.A. |
Pegylierte liposomen zur auslieferung von immunogen-kodierende rns
|
BR112013004865A2
(pt)
|
2010-08-31 |
2016-06-07 |
Novartis Ag |
lípidos adequados para entrega lipossomal de codificadores de proteínas rna
|
PL2611467T3
(pl)
|
2010-08-31 |
2022-08-16 |
Glaxosmithkline Biologicals Sa |
Małe liposomy do dostarczania rna kodującego immunogen
|
WO2012034025A2
(en)
*
|
2010-09-09 |
2012-03-15 |
Virginia Commonwealth University |
Human cytomegalovirus vaccine
|
HUE058896T2
(hu)
|
2010-10-01 |
2022-09-28 |
Modernatx Inc |
N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
|
TR201903651T4
(tr)
|
2010-10-11 |
2019-04-22 |
Glaxosmithkline Biologicals Sa |
Antijen uygulama platformları.
|
CA2815664C
(en)
|
2010-10-25 |
2018-04-17 |
Stepan Company |
Quaternized fatty amines, amidoamines, and their derivatives from natural oil metathesis
|
US9405700B2
(en)
|
2010-11-04 |
2016-08-02 |
Sonics, Inc. |
Methods and apparatus for virtualization in an integrated circuit
|
ES2727836T3
(es)
|
2011-01-26 |
2019-10-21 |
Glaxosmithkline Biologicals Sa |
Régimen de inmunización del VRS
|
WO2012106377A2
(en)
|
2011-01-31 |
2012-08-09 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
US8710200B2
(en)
|
2011-03-31 |
2014-04-29 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids encoding a modified erythropoietin and their expression
|
CA2835644C
(en)
|
2011-05-13 |
2021-06-15 |
Novartis Ag |
Pre-fusion rsv f antigens
|
CN103687957A
(zh)
|
2011-05-17 |
2014-03-26 |
现代治疗公司 |
工程化核酸及其用于非人类脊椎动物的方法
|
AU2012267578B2
(en)
|
2011-06-08 |
2017-04-20 |
Translate Bio, Inc. |
Cleavable lipids
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
JP2014520806A
(ja)
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
Rna分子の送達のための有用なn:p比を有するリポソーム
|
RU2606846C2
(ru)
|
2011-07-06 |
2017-01-10 |
Новартис Аг |
Эмульсии типа "масло в воде", которые содержат нуклеиновые кислоты
|
ES2702318T3
(es)
|
2011-07-06 |
2019-02-28 |
Glaxosmithkline Biologicals Sa |
Emulsiones catiónicas de aceite en agua
|
MX366055B
(es)
*
|
2011-08-31 |
2019-06-26 |
Novartis Ag |
Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
|
EP3384938A1
(de)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Manipulierte nukleinsäuren und verfahren zur verwendung davon
|
RS62993B1
(sr)
|
2011-10-03 |
2022-03-31 |
Modernatx Inc |
Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
|
AU2012322704B2
(en)
|
2011-10-11 |
2017-09-07 |
Novartis Ag |
Recombinant self-replicating polycistronic RNA molecules
|
WO2013054199A2
(en)
|
2011-10-12 |
2013-04-18 |
Novartis Ag |
Cmv antigens and uses thereof
|
EP2791364A4
(de)
|
2011-12-14 |
2015-11-11 |
Moderna Therapeutics Inc |
Verfahren zur reaktion auf eine biologische bedrohung
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
CA2859691A1
(en)
|
2011-12-21 |
2013-06-27 |
Moderna Therapeutics, Inc. |
Methods of increasing the viability or longevity of an organ or organ explant
|
DE18200782T1
(de)
|
2012-04-02 |
2021-10-21 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
|
JP2015518705A
(ja)
|
2012-04-02 |
2015-07-06 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
|
EP4074834A1
(de)
|
2012-11-26 |
2022-10-19 |
ModernaTX, Inc. |
Am kettenende modifizierte rna
|
WO2014108515A1
(en)
|
2013-01-10 |
2014-07-17 |
Novartis Ag |
Influenza virus immunogenic compositions and uses thereof
|
US9504747B2
(en)
|
2013-03-08 |
2016-11-29 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
EP2971010B1
(de)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
US10059655B2
(en)
|
2013-12-19 |
2018-08-28 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
SI3350157T1
(sl)
|
2015-09-17 |
2022-04-29 |
Modernatx, Inc. |
Sestave za doziranje terapevtskih sredstev v celice
|
AU2016343803B2
(en)
|
2015-10-28 |
2021-04-29 |
Acuitas Therapeutics, Inc. |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
CN110114058B
(zh)
|
2016-11-10 |
2023-05-26 |
川斯勒佰尔公司 |
用于递送mrna的改进的基于ice的脂质纳米颗粒制剂
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
AU2019384557A1
(en)
|
2018-11-21 |
2021-06-10 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
|
EP4021407A1
(de)
|
2019-08-30 |
2022-07-06 |
GlaxoSmithKline Biologicals S.A. |
Strahlmischherstellungsverfahren zum herstellung für lipid-nanopartikel
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|